Table 2 Summary of the sensitivity and specificity for T790Â M mutation testing based on various plasma assay platforms
From: Third generation EGFR TKIs: current data and future directions
Plasma Assays | Sensitivity n/N (%) | Specificity n/N (%) | Plasma T790Â M positive / histology negative (%) | Reference | |||
|---|---|---|---|---|---|---|---|
EGFR | T790Â M after PD on TKI | EGFR | T790Â M after PD on TKI | ||||
Digital PCR, Microdroplet | BEAMing | 49/60 (81.7) | 33/45 (73.3) | 2/3 (66.7) | 9/18 (50) | 9/18 (50) | Karlovich 2016 (Roci) |
43/51 (84.3) | 33/41 (80.5) | 65/67 (97.0) | 14/24 (58.3) | 10/24 (41.7) | Thress 2015 (AURA) | ||
112/136 (82.3) | 111/158 (70.3) | 78/80 (97.5) | 40/58 (69.0) | 18/40 (31.0) | Oxnard 2016 | ||
ddPCR | NA | 6/9 (66.7) | NA | 5/7 (71.4) | 2/7 (28.6) | Wang 2017 | |
25/33 (75.7) | 20/31 (64.5) | 7/8 (87.5) | 7/10 (70) | 3/10 (30) | Takahama 2016 (West Japan Oncology Group) | ||
9/10 (90) | 12/17 (70.5) | 28/28 (100) | 5/6 (83.3) | 1/6 (16.7) | Thress 2015 (AURA) | ||
Allele -specific PCR | ARMS, Therascreen | 30/37 (81.1) | 5/17 (29.4) | 38/38 (100) | 6/6 (100) | 0 | Thress 2015 (AURA) |
Roche cobas® AS-PCR | 43/51 (84.3) | 30/41 (73.2) | 65/67 (97.0) | 16/24 (66.7) | 8/24 (33.3) | Thress 2015 (AURA) | |
55/75 (73.3) | 21/33 (63.6) | 24/24 (100) | 61/62 (98.4) | 1/62 (1.6) | Karlovich et al. 2016 (Roci) | ||
NA | 254/414 (61.3) | NA | 99/126 (78.6) | 27/126 (21.4) | Jenkins 2017 (AURA ext. + AURA2 pooled), excluded those with unknown plasma results | ||
13/16 (81.2) | 6/10 (60.0) | 30/30 (100) | 9/15 (60) | 6/15 (40) | Sundaresan 2016 | ||
CTCs | NA | 5/9 (55.5) | NA | 7/12 (58.2) | 5/12 (41.7) | Sundaresan 2016 | |